Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Self-control Trial to Evaluate the Remission Rate and Safety in Newly Diagnosed Type 2 Diabetes Patients After Short-term Intensive Insulin Aspart and Insulin NPH Treatment

NCT00494988 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00494988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Self-control Trial to Evaluate the Remission Rate and Safety in Newly Diagnosed Type 2 Diabetes Patients After Short-term Intensive Insulin Aspart and Insulin NPH Treatment
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2004
Completion date
April 30, 2006
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2